



ASX / MEDIA RELEASE

Investor Conference Call

Brisbane, Australia, 30 October 2018 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, will host a conference call on **Wednesday 31 October 2018 at 11am AEDT** to discuss the preliminary results from its SMARTCOUGH-C-2 clinical study. Tony Keating, Managing Director and CEO, will host the call.

Conference Call Details:

Date: Wednesday 31 October, 11am AEDT

Conference ID: 6195379

Access: Australia: +61 2 8038 5221
New Zealand: 0800 452 782
China: 4001 203 085
Hong Kong: 800 908 865
Singapore: 800 616 2288
United Kingdom: 0808 234 0757
United States: 1855 293 1544

Participants will need to provide their name and to ask a question, they will need to dial “*1” (star, 1) on their telephone keypad.

A recording will be available four hours after the end of the call on openbriefing.com.

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals in the United States and Australia have demonstrated accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnoea in a double-blind, prospective clinical study. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world.

For more information on ResApp, visit www.resapphealth.com.au

ResApp Health Limited ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 24, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 E info@resapphealth.com.au W www.resapphealth.com.au



Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au